Opiant Pharmaceuticals, Inc.

NasdaqCM:OPNT 주식 보고서

시가총액: US$108.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Opiant Pharmaceuticals 관리

관리 기준 확인 2/4

Opiant Pharmaceuticals CEO는 Roger Crystal, Sep2009 에 임명되었습니다 의 임기는 13.5 년입니다. 총 연간 보상은 $ 1.48M, 42.9% 로 구성됩니다. 42.9% 급여 및 57.1% 보너스(회사 주식 및 옵션 포함). 는 $ 695.26K 가치에 해당하는 회사 주식의 0.64% 직접 소유합니다. 695.26K. 경영진과 이사회의 평균 재임 기간은 각각 5.5 년과 6.8 년입니다.

주요 정보

Roger Crystal

최고 경영자

US$1.5m

총 보상

CEO 급여 비율42.9%
CEO 임기13.5yrs
CEO 소유권0.6%
경영진 평균 재임 기간5.5yrs
이사회 평균 재임 기간6.8yrs

최근 관리 업데이트

Recent updates

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates

Aug 13
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates

Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment

Aug 08

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate

Aug 05
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate

Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts

Mar 21
Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts

Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News

Nov 19
Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News

These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well

Nov 17
These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well

Opiant Pharmaceuticals: Assessing Recent Insider Buying

Sep 19

Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts

Aug 07
Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts

Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)

Jun 09
Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)

The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts

Mar 06
The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts

News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts

Mar 05
News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts

Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.

Jan 27
Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.

Opiant Pharma secures additional BARDA grant of $3.5M for OPNT003

Dec 14

Opiant Pharmaceuticals receives $50M in convertible debt financing

Dec 10

CEO 보상 분석

Roger Crystal 의 보수는 Opiant Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2022n/an/a

-US$33m

Jun 30 2022n/an/a

-US$20m

Mar 31 2022n/an/a

-US$6m

Dec 31 2021US$1mUS$635k

US$3m

Sep 30 2021n/an/a

US$2m

Jun 30 2021n/an/a

-US$1m

Mar 31 2021n/an/a

-US$3m

Dec 31 2020US$1mUS$610k

-US$2m

Sep 30 2020n/an/a

-US$108k

Jun 30 2020n/an/a

US$10m

Mar 31 2020n/an/a

US$12m

Dec 31 2019US$1mUS$592k

US$12m

Sep 30 2019n/an/a

US$988k

Jun 30 2019n/an/a

-US$11m

Mar 31 2019n/an/a

-US$14m

Dec 31 2018US$865kUS$574k

-US$21m

Sep 30 2018n/an/a

-US$2m

Jun 30 2018n/an/a

-US$5m

Mar 31 2018n/an/a

-US$3m

Dec 31 2017n/an/a

US$3m

Oct 31 2017n/an/a

US$2m

Jul 31 2017US$1mUS$568k

US$7m

Apr 30 2017n/an/a

US$6m

Jan 31 2017n/an/a

US$9m

Oct 31 2016n/an/a

US$3m

Jul 31 2016US$5mUS$616k

-US$8m

보상 대 시장: Roger 의 총 보상 ($USD 1.48M )은 US 시장( $USD 646.00K ).

보상과 수익: 회사가 수익성이 없는 동안 Roger 의 보상이 증가했습니다.

CEO

Roger Crystal (46 yo)

13.5yrs

테뉴어

US$1,477,846

보상

Dr. Roger Crystal, M.D., has been an Independent Director of Mind Medicine (MindMed) Inc. since August 11, 2022. Dr. Crystal has been the Chief Executive Officer of Opiant Pharmaceuticals, Inc. since Septe...

리더십 팀

이름위치테뉴어보상소유권
Roger Crystal
President13.5yrsUS$1.48m0.64%
$ 695.3k
David O'Toole
Chief Financial Officer5.5yrsUS$786.67k0.43%
$ 464.9k
Phillip Skolnick
Chief Scientific Officer6.1yrsUS$800.11k0.19%
$ 202.6k
Ben Atkins
Vice President of Communications & Investor Relationsno data데이터 없음데이터 없음
Brian Gorman
EVP Corporate Development & General Counsel2.6yrs데이터 없음0.34%
$ 369.9k
Mark Ellison
Chief Development Officerno data데이터 없음0.36%
$ 387.2k
Matthew Ruth
Chief Commercial Officer1.7yrs데이터 없음0.13%
$ 137.7k

5.5yrs

평균 재임 기간

57.5yo

평균 연령

경험이 풍부한 관리: OPNT 의 관리팀은 노련하고 경험 (평균 재직 기간 5.5 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Roger Crystal
President13.5yrsUS$1.48m0.64%
$ 695.3k
Michael Sinclair
Independent Director12.3yrsUS$42.70k1.14%
$ 1.2m
Thomas Thomas
Independent Director6.3yrsUS$113.70k0.20%
$ 214.2k
Craig Collard
Independent Chairman4.4yrsUS$137.20k1.02%
$ 1.1m
Thomas Kosten
Member of Medical Advisory Boardno data데이터 없음데이터 없음
Ann MacDougall
Independent Director6.8yrsUS$109.70k0.50%
$ 540.6k
Sharon Walsh
Chairwoman of Medical Advisory Boardno data데이터 없음데이터 없음
Sandra Comer
Member of Medical Advisory Boardno data데이터 없음데이터 없음
Marc Potenza
Member of Medical Advisory Boardno data데이터 없음데이터 없음
Gabrielle Silver
Independent Director6.8yrsUS$103.70k0.41%
$ 440.7k
Stephanie O'Malley
Member of Medical Advisory Boardno data데이터 없음데이터 없음
Wim van den Brink
Member of Medical Advisory Boardno data데이터 없음데이터 없음

6.8yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 이사회: OPNT 의 이사회는 경험(평균 재직 기간 6.8 년)으로 간주됩니다.